New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 25, 2014
09:11 EDTMRK, X, RGDO, THI, ADXS, TRP, RHHBY, BKW, QIHU, INSY, ITMNOn The Fly: Pre-market Movers
HIGHER: Burger King (BKW), up 13% after confirming talks regarding a potential strategic transaction with Tim Hortons (THI). Shares of the Canadian donut shop operator trading in New York are also up 17%... InterMune (ITMN), up 36% after Roche (RHHBY) agreed to acquire the company for $74.00 per share... Advaxis (ADXS), up 4% after entering clinical trial collaboration agreement with Merck (MRK)... Insys Therapeutics (INSY), up 5.5% after receiving FDA orphan drug designation for CBD... TransCanada (TRP), up 2.2% after Barron's says the company could climb 35%... U.S. Steel (X), up 3.7% after upgraded at Credit Suisse. LOWER: Regado (RGDO), down 52% after the company terminated enrollment in its REGULATE-PCI Phase 3 trial... Qihoo 360 (QIHU), down 5% after reporting Q2 earnings, Q3 outlook.
News For BKW;THI;ITMN;RHHBY;RGDO;INSY;TRP;X;QIHU;ADXS;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 27, 2015
10:57 EDTQIHUOptions with increasing implied volatility
Subscribe for More Information
07:51 EDTRHHBYRoche catching up fast to Bristol-Myers in immuno-oncology, says Jefferies
Subscribe for More Information
August 26, 2015
08:53 EDTMRKMerck management to meet with SunTrust
Subscribe for More Information
08:05 EDTADXSAdvaxis enters licensing agreement with Knight Therapeutics
Advaxis announced that the company has entered into a licensing agreement with Knight Therapeutics to commercialize in Canada Advaxis's product portfolio including its three lead drug candidates: axalimogene filolisbac for human papilloma virus, or HPV,-associated cancers, ADXS-PSA for prostate cancer and ADXS-HER2 for HER2 expressing solid tumors. In connection with the licensing agreement, Knight is purchasing directly from Advaxis 359,454 shares at $13.91 per share, which represents a 7% premium to the price of Advaxis's common stock at market close on August 25. In addition, Sectoral Asset Management, a leading Canadian-based global healthcare investment advisor, is purchasing 1.44M shares at $13.91 per share directly from Advaxis on behalf of its clients. The combined gross proceeds to Advaxis from these direct investments is $25M.
August 24, 2015
12:01 EDTRHHBYRoche buys nucleic acid purification technology from Lumora
Roche has signed a definitive asset purchase agreement with Lumora for products associated with the patent-protected Heat Elution technology for nucleic acid purification of multiple sample types including challenging formalin-fixed paraffin-embedded tumor samples. Roche plans to explore integrating this technology into its sequencing workflow solution.
10:32 EDTXU.S. Steel says acted to effectuate hard freeze of some benefits
In a regulatory filing from Friday evening, U.S. Steel disclosed that on August 17, United States Steel Corporation, acted to effectuate a hard freeze of benefits accrued under each of the following plans effective as of December 31, 2015: (i) the United States Steel Corporation Plan for Employee Pension Benefits and each provision, rule part, plan or program thereunder as applicable to non-union employees; (ii) the United States Steel Corporation Non Tax-Qualified Pension Plan; and (iii) the United States Steel Corporation Executive Management Supplemental Pension Program. As a result, from and after December 31 all benefit accruals under each Plan shall cease and no participant in any Plan will receive credit under the Plan for further service to the Corporation or its subsidiaries and the compensation levels resulting from any such further service will not be relevant to the determination of benefits payable under the Plans. The Non Tax-Qualified Plan and the Supplemental Plan provide benefits to Mr. Douglas Matthews, one of our Named Executive Officers. As described above, on August 1 , the Corporation enacted a hard freeze of benefits accrued under its DB Plan effective December 31. Participants of the DB Plan will be transitioned to a defined contribution retirement plan at that time. The Corporation will perform a remeasurement of the DB Plan, and will report these results in its quarterly report on Form 10-Q for the quarter ended September 30.
10:05 EDTTRPTransCanada reaches agreement with Eastern LDCs on Energy East
Subscribe for More Information
09:18 EDTXOn The Fly: Pre-market Movers
Subscribe for More Information
August 23, 2015
13:07 EDTXU.S. Steel shares could rally 60% to $28 by late 2016, Barron's says
Shares of U.S. Steel could rise more than 60% to $28 by the end of 2016 as steel prices increase, cost cutting measures take effect, and Chinese imports decline given an import tariff scheduled for November, Barron's contends in a feature article. Reference Link
12:35 EDTRHHBY, MRKBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
09:38 EDTRHHBYUBS global healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
08:26 EDTXU.S. Steel initiated with a Sell at Axiom
Subscribe for More Information
05:44 EDTMRKStocks with implied volatility movement; DIS MRK
Subscribe for More Information
August 20, 2015
11:33 EDTMRKLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
09:23 EDTADXSAdvaxis, MedImmune begin enrollment in axalimogene filolisbac Phase I/II study
Subscribe for More Information
08:38 EDTMRKMerck says to present new analyses from IMPROVE-IT study
Subscribe for More Information
05:46 EDTQIHUStocks with implied volatility movement; QIHU EOG
Stocks with implied volatility movement; Qihoo 360 (QIHU) 45, EOG Resources (EOG) 35 according to iVolatility.
August 18, 2015
12:13 EDTMRKMerck recalls Temodar, Temozolomide bottles with cracked caps
Subscribe for More Information
08:16 EDTINSYInsys Therapeutics files citizen petition with DEA to reschedule synthetic CBD
Insys Therapeutics announced it has filed a Citizen Petition with the DEA to request the agency reschedule its synthetic pharmaceutical cannabidiol, or CBD, from Schedule I to Schedule IV. The company believes that the current classification of synthetic CBD as a Schedule I compound is a significant barrier to the progress of research studies that explore the value of this compound in the treatment of several serious medical conditions.
08:03 EDTMRKMerck says FDA accepts sBLA for Keytruda
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use